Seymour, J F
Kim, D W
Rubin, E
Haregewoin, A
Clark, J
Watson, P
Hughes, T
Dufva, I
Jimenez, J L
Mahon, F-X
Rousselot, P
Cortes, J
Martinelli, G
Papayannidis, C
Nagler, A
Giles, F J
Article History
Received: 5 June 2014
Accepted: 17 June 2014
First Online: 15 August 2014
Competing interests
: ER and PW are employees of and may own stock in Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Whitehouse Station, NJ, USA. FJG received a grant from Merck for this study. TH received grants from Novartis, BMS and ARIAD outside the submitted work. JLJ received a grant from Merck outside the submitted work. JCortes received grants and consulting fees from ARIAD, BMS, Novartis, Pfizer and Teva outside the submitted work. JClark is an employee of Incyte Corporation. GM received personal fees from Novartis, Roche, BMS and Pfizer outside the submitted work. DWK received a grant from Novartis during this study, honoraria from Novartis, BMS and ILYANG, and a grant from Pfizer outside the submitted work. JFS, AN, PR, F-XM, ID, AH and CP have no conflict of interest to disclose.